Unveiling 6 Analyst Insights On Liquidia

6 analysts have expressed a variety of opinions on Liquidia LQDA over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.0, with a high estimate of $30.00 and a low estimate of $3.00. This current average has increased by 18.92% from the previous average price target of $18.50.

Decoding Analyst Ratings: A Detailed Look

The standing of Liquidia among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Liquidia. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Liquidia compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Liquidia's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Liquidia's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Liquidia analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

Liquidia: Delving into Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Liquidia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.21% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -429.31%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Liquidia's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -29.06%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Liquidia's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.54%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Liquidia's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.

How Are Analyst Ratings Determined?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.